Position in DNLI
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$200,075
-$587,978 QoQ
Shares Held
7,779
-79.9% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#198
of 290 holders
Holding Since
Sep 2022
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FOX RUN MANAGEMENT, L.L.C. holds $29,784,980 across 59 Biotechnology names. DNLI ranks #53 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NAMS |
NewAmsterdam Pharma Co N.V.
|
59,477 | $2,015,675 | |
| 2 | RPRX |
Royalty Pharma plc
|
24,094 | $1,350,950 | |
| 3 | IMVT |
Immunovant, Inc.
|
34,827 | $1,341,884 | |
| 4 | ASND |
Ascendis Pharma A/S
|
4,726 | $1,260,518 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
28,315 | $1,104,568 | |
| 6 | ARQT |
Arcutis Biotherapeutics, Inc.
|
38,178 | $1,001,027 | |
| 7 | EXEL |
Exelixis, Inc.
|
18,255 | $993,254 | |
| 8 | EYPT |
EyePoint, Inc.
|
58,528 | $836,950 |
All Filings in DNLI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $200,075 | 7,779 | Shares | Sole | 2026-08-04 | |
| 2024-12-31 | $788,053 | 38,668 | Shares | Sole | 2025-02-11 | |
| 2024-06-30 | $566,335 | 24,390 | Shares | Sole | 2024-08-13 | |
| 2023-06-30 | $368,225 | 12,478 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | $205,447 | 8,917 | Shares | Sole | 2023-05-12 | |
| 2022-09-30 | $459,644 | 14,977 | Shares | Sole | 2022-11-07 | |
| No filing history on record for this holder in this stock. | ||||||